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Introduction: Inverted Papilloma (IP) of the bladder is an
infrequent event (2.2% of all cancers of the bladder) (Picozzi,
Urol Oncol 2012). The IP of the upper urinary tract and in
particular of the renal pelvis is exceptionally rare. We
performed a systematic review of the literature on this unusual
pathological findings. Materials and Methods: We carried out
a systematic research from January 1974 to January 2013 on
the Medline, Embase and Cochrane Library using the key
words: “renal inverted papilloma”, “inverted papilloma of the
upper urinary tract” “inverted papilloma kidney”, restricted to
English articles. Results: We identify 39 articles in literature
and 14 are included in this review, for a total of 19 clinical
cases. The mean age of presentation of renal IP was 65.1 years
(range 49 to 89), with a male/female ratio of 18/1. In 1 case
(5.3%) the clinical presentation of the IP is synchronous with
a carcinoma of the bladder (3) and in another case with an
urothelial neoplasm on the controlateral kidney (2). The
finding of IP in the kidney was incidental in 10 cases (52.6%),
in 5 cases (26.3%) there was documented hematuria and flank
pain in 2 cases (10.5%). The lesion was identified by CT in
13 cases (68.4%) and by urography in 6 cases (31.6%). In 15
cases (79.0%) a nephrectomy or nephroureterectomy was
performed, and in 3 cases (15.78%) a local excision of the
lesion by ureterorenoscopy or pielotomy. In 3 cases (15.8%)
local relapse has been described, and in one case (5.3%)
worsening of the disease in a urothelial cancer (4). Discussion:
An analysis of the literature on this rare disease has shown
that, despite IP is classified as a benign lesion, in 10% of cases
it may be associated with other carcinoma of the urinary tract
and in one case out of five may recur or develop into
malignancy. Instrumental investigation can not suggest any
distinctive features of these lesions such as to allow a
differential diagnosis with urothelial carcinoma. In fact in the
most of the cases the patients were subjected to nephrectomy
or nephroureterectomy. Considering the possible association
with malignancy, the tendency of these lesions to relapse and
the rare malignant progression, a close follow-up is
recommended like the model used for the conventional renal
tumor. Conclusion: The IP of the kidney is an uncommon
disease, which requires accurate characterization by the
pathologist for the risk of malignant lesions and close
monitoring by the urologist for the risk of local recurrence or
malignant degeneration. 
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Background and Aims: Gonadotropin-releasing hormone
(GnRH) agonists are used in the standard treatment of
advanced prostate cancer. More recently, GnRH antagonists
have been developed and compared versus GnRH agonists in
clinical trials. GnRH analogues act via specific GnRH-
receptors and block the pituitary-gonadal axis. Nevertheless,
it has been widely demonstrated in vitro that GnRH agonists
exert a direct effect on tumor cells. There are fewer data on
the antagonists, but no information is available about the direct
effect of a new analogue of third generation named Degarelix.
In this study, the antiproliferative effect of Degarelix on three
human prostate cancer cell lines (LNCaP, androgen-sensitive;
DU145 and PC3, androgen-independent) was explored.
Methods: Cells were grown in their standard culture
ANTICANCER RESEARCH 34: 2593-2686 (2014)
2674
